» Articles » PMID: 28231771

Novel Synthetic Analogues of Avian β-defensin-12: the Role of Charge, Hydrophobicity, and Disulfide Bridges in Biological Functions

Overview
Journal BMC Microbiol
Publisher Biomed Central
Specialty Microbiology
Date 2017 Feb 25
PMID 28231771
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Avian β-defensins (AvBD) possess broad-spectrum antimicrobial, LPS neutralizing and chemotactic properties. AvBD-12 is a chemoattractant for avian immune cells and mammalian dendritic cells (JAWSII) - a unique feature that is relevant to the applications of AvBDs as chemotherapeutic agents in mammalian hosts. To identify the structural components essential to various biological functions, we have designed and evaluated seven AvBD analogues.

Results: In the first group of analogues, the three conserved disulfide bridges were eliminated by replacing cysteines with alanine and serine residues, peptide hydrophobicity and charge were increased by changing negatively charged amino acid residues to hydrophobic (AvBD-12A1) or positively charged residues (AvBD-12A2 and AvBD-12A3). All three analogues in this group showed improved antimicrobial activity, though AvBD-12A3, with a net positive charge of +9, hydrophobicity of 40% and a predicted CCR2 binding domain, was the most potent antimicrobial peptide. AvBD-12A3 also retained more than 50% of wild type chemotactic activity. In the second group of analogues (AvBD-12A4 to AvBD-12A6), one to three disulfide bridges were removed via substitution of cysteines with isosteric amino acids. Their antimicrobial activity was compromised and chemotactic activity abolished. The third type of analogue was a hybrid that had the backbone of AvBD-12 and positively charged amino acid residues AvBD-6. The antimicrobial and chemotactic activities of the hybrid resembled that of AvBD-6 and AvBD-12, respectively.

Conclusions: While the net positive charge and charge distribution have a dominating effect on the antimicrobial potency of AvBDs, the three conserved disulfide bridges are essential to the chemotactic property and the maximum antimicrobial activity. Analogue AvBD-12A3 with a high net positive charge, a moderate degree of hydrophobicity and a CCR2-binding domain can serve as a template for the design of novel antimicrobial peptides with chemotactic property and salt resistance.

Citing Articles

cell-wall and antimicrobial peptides: a mission impossible?.

Jacobo-Delgado Y, Rodriguez-Carlos A, Serrano C, Rivas-Santiago B Front Immunol. 2023; 14:1194923.

PMID: 37266428 PMC: 10230078. DOI: 10.3389/fimmu.2023.1194923.


Identification of prognostic hub genes and therapeutic targets for selenium deficiency in chicks model through transcriptome profiling.

Lingamgunta L, Aloor B, Dasari S, Ramakrishnan R, Botlagunta M, Madikonda A Sci Rep. 2023; 13(1):8695.

PMID: 37248251 PMC: 10226025. DOI: 10.1038/s41598-023-34955-6.


Evolutionary and guided development of novel peptide analogues for antibacterial activity against ESKAPE pathogens.

Lata M, Telang V, Gupta P, Pant G, Kalyan M, Arockiaraj J Curr Res Microb Sci. 2023; 4:100183.

PMID: 37032813 PMC: 10073642. DOI: 10.1016/j.crmicr.2023.100183.


Antimicrobial Peptides: From Design to Clinical Application.

Zhang C, Yang M Antibiotics (Basel). 2022; 11(3).

PMID: 35326812 PMC: 8944448. DOI: 10.3390/antibiotics11030349.


Clinical Applications and Anticancer Effects of Antimicrobial Peptides: From Bench to Bedside.

Jafari A, Babajani A, Sarrami Forooshani R, Yazdani M, Rezaei-Tavirani M Front Oncol. 2022; 12:819563.

PMID: 35280755 PMC: 8904739. DOI: 10.3389/fonc.2022.819563.


References
1.
Chu H, Yu H, Yip B, Chih Y, Liang C, Cheng H . Boosting salt resistance of short antimicrobial peptides. Antimicrob Agents Chemother. 2013; 57(8):4050-2. PMC: 3719776. DOI: 10.1128/AAC.00252-13. View

2.
Ernst C, Staubitz P, Mishra N, Yang S, Hornig G, Kalbacher H . The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog. 2009; 5(11):e1000660. PMC: 2774229. DOI: 10.1371/journal.ppat.1000660. View

3.
Soulsby E . Resistance to antimicrobials in humans and animals. BMJ. 2005; 331(7527):1219-20. PMC: 1289307. DOI: 10.1136/bmj.331.7527.1219. View

4.
Mandal M, Jagannadham M, Nagaraj R . Antibacterial activities and conformations of bovine beta-defensin BNBD-12 and analogs:structural and disulfide bridge requirements for activity. Peptides. 2002; 23(3):413-8. DOI: 10.1016/s0196-9781(01)00628-3. View

5.
de Paula V, Gomes N, Lima L, Miyamoto C, Monteiro R, Almeida F . Structural basis for the interaction of human β-defensin 6 and its putative chemokine receptor CCR2 and breast cancer microvesicles. J Mol Biol. 2013; 425(22):4479-95. DOI: 10.1016/j.jmb.2013.08.001. View